Developer docs
API playgroundTry for free, no card

Search company profiles

Aurion Biotechnologies

Full company profile

uuid00007lz

Namestring
Aurion Biotechnologies
Legal namestring
Aurion Biotech, Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Aurion Biotech is a clinical-stage regenerative cell therapy company developing first-in-class allogeneic therapies for corneal endothelial disease. The company's Corneal Endothelial Cell Therapy (CECT) platform uses natural, unmodified human corneal endothelial cells (neltependocel) delivered with a rho-kinase inhibitor (Y-27632) via intracameral injection. A single donor cornea can yield up to 1,000 therapeutic doses, addressing the documented 1:70 global imbalance between donor corneas and diseased eyes. The portfolio comprises Vyznova (commercial in Japan since 2024 for bullous keratopathy), AURN001 (U.S. Phase 3 with FDA Breakthrough Therapy and RMAT designations), and a cryopreserved formulation in earlier development.

The company generates revenue through commercial sales of Vyznova in Japan following PMDA approval in 2024, with pricing not publicly disclosed and operated on a quote/reimbursement-driven model. U.S. revenue is pre-commercial, pending BLA submission supported by the ASTRA Phase 3 trial initiated at 12 U.S. sites in April 2026. Go-to-market relies on enterprise field sales targeting ophthalmologists and corneal surgeons, with Alcon's majority ownership (2025) providing potential distribution leverage. Aurion's leadership combines deep cell therapy expertise (CEO/CSO Arnaud Lacoste, ex-Novartis cell/gene therapy) with established ophthalmology credentials (CMO Edward Holland, Cincinnati Eye Institute).

Aurion was founded to commercialize foundational research from Professor Shigeru Kinoshita at Kyoto Prefectural University of Medicine, and is now majority-owned by Alcon following the 2025 acquisition. The company is headquartered in Cambridge, MA, with operations in Seattle and Tokyo, and was backed by $120 million in Series A funding led by Deerfield Management in April 2022.

Short descriptiontext

Aurion Biotech is a clinical-stage regenerative cell therapy company developing allogeneic corneal endothelial cell therapies (neltependocel with rho-kinase inhibitor) for corneal endothelial disease, with Vyznova commercial in Japan and AURN001 in U.S. Phase 3 development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
corneal cell therapy, regenerative ophthalmology, endothelial disease treatment, allogeneic cell therapy, ophthalmic biologics
Industry3 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Vyznova Commercial Sales (Japan)
TypeOne Time License
Description

Aurion Biotech generates revenue from commercial sales of Vyznova in Japan, where it received regulatory and reimbursement approval in 2024. Vyznova is the first cell therapy for corneal endothelial disease commercially available in Japan, indicated for bullous keratopathy.

aurionbiotech.com
2AURN001 (Future U.S. Commercialization)
TypeOne Time License
Description

AURN001 is in Phase 3 development in the U.S. with Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation. Upon FDA approval, the company anticipates commercializing AURN001 as the first cell therapy for corneal endothelial disease in the U.S. market.

aurionbiotech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Vyznova
Description

First-generation corneal endothelial cell therapy approved by Japan's PMDA for patients with bullous keratopathy. Commercially available in Japan since 2024.

aurionbiotech.com
+1 more record
Core offering1 text field

Aurion Biotech develops and manufactures allogeneic cell therapies for corneal endothelial disease, including commercially available Vyznova in Japan and investigational AURN001 in U.S. Phase 3 development. The therapy uses cultured human corneal endothelial cells (neltependocel) combined with a rho-kinase inhibitor (Y-27632), delivered as an intracameral injection to regenerate the corneal endothelium and restore vision. The platform's manufacturing scale enables up to 1,000 therapeutic doses from a single donor cornea.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 65% of high-dose AURN001 patients achieved ≥15-letter BCVA improvement vs 0% in control group (p<0.0001)
+5 more records
Product overview1 text field

Aurion Biotech is a regenerative cell therapy company developing first-in-class therapies for corneal endothelial disease. The portfolio consists of Vyznova (commercially available in Japan since 2024) as the first-generation product, AURN001 as the lead investigational candidate in U.S. Phase 3 development with BTD/RMAT designation, and a cryopreserved formulation of AURN001 in earlier development to improve distribution accessibility. All products utilize cultured human corneal endothelial cells combined with rho-kinase inhibitor to regenerate corneal clarity.

Product and service3 records
1Vyznova
CategoryCommercial Cell Therapy Product
Description

First-generation corneal endothelial cell therapy approved by Japan's PMDA for patients with bullous keratopathy. Built on a decade of pioneering clinical research in endothelial cell injection, Vyznova is commercially available in Japan since 2024 and is administered to Japanese ophthalmologists and corneal surgeons for the treatment of bullous keratopathy.

2AURN001
CategoryInvestigational Cell Therapy Product
Description

First-in-class combination therapy consisting of natural, unmodified donor endothelial cells (neltependocel) delivered with a rho-kinase inhibitor (Y-27632). Designed to regenerate corneal clarity by repopulating the posterior cornea with functional donor cells. Currently in Phase 3 development in the U.S. with FDA Breakthrough Therapy and RMAT designations granted.

3Cryopreserved AURN001 Formulation
CategoryPipeline Cell Therapy Program
Description

Pipeline program evaluating a cryopreserved formulation of Aurion's endothelial cell therapy in clinical study. Being developed to support broader distribution and treatment accessibility beyond the current fresh-cell formulation.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Aurion Biotech is an affiliate member of the EBAA. The company presented at EBAA's 2026 Annual Meeting in Indianapolis, participating in a panel on Innovative Solutions. The relationship focuses on education and awareness about regenerative cell therapy as an alternative to traditional transplantation.

2Kyoto Prefectural University of Medicine
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Professor Shigeru Kinoshita's foundational technology from Kyoto Prefectural University of Medicine underlies Aurion's cell therapy development. His pioneering research in corneal endothelial cell transplantation provided the scientific foundation for the company's therapeutic approach.

aurionbiotech.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic cell therapies for ophthalmic indications. Directly comparable as a peer cell therapy developer in ophthalmology, though focused on retinal indications rather than cornea.

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic cell therapies for ophthalmology and other indications. Closely comparable as an allogeneic cell therapy developer targeting vision loss with similar manufacturing and regulatory profiles.

TypeDirect peer
Description

Corneal tissue provider and ophthalmology services company serving corneal surgeons with donor tissue and surgical solutions. Direct peer addressing the same corneal surgeon customer base, though operating in the donor tissue supply chain rather than cell therapy.

TypeBroad incumbent
Description

Global pharmaceutical company with significant regenerative medicine and cell therapy interests, including historical work on ophthalmology cell therapy via the Astellas Institute for Regenerative Medicine. Comparable as a large incumbent with overlapping cell therapy R&D capabilities.

TypeBroad incumbent
Description

Commercial-stage ophthalmology biopharmaceutical company developing therapies for retinal diseases and other eye conditions. Comparable as an ophthalmology-focused biotech with drug delivery and specialty therapeutic capabilities targeting eye care specialists.

TypeBroad incumbent
Description

Specialty ophthalmology company developing sustained-release drug delivery technologies for eye diseases. Comparable as an ophthalmology-focused company addressing unmet needs in vision-threatening conditions with novel delivery approaches.

TypeBroad incumbent
Description

Global ophthalmology company with a broad portfolio of surgical, pharmaceutical, and consumer eye care products. Comparable as a broad incumbent with established ophthalmology commercial infrastructure and surgical vision care offerings.

TypeBroad incumbent
Description

Medical technology company focused on novel interventional treatments for glaucoma and corneal disorders. Comparable as an ophthalmology-focused company addressing surgical and disease-modifying therapies in eye care.

TypeEmerging player
Description

Commercial-stage biotech pioneering a topical gene therapy platform. Comparable as an emerging biotech applying novel biological platforms to rare diseases with a focus on genetic and regenerative approaches, though in dermatology rather than ophthalmology.

TypeEmerging player
Description

Commercial-stage ophthalmology company developing adjustable intraocular lens technology for cataract surgery. Comparable as an emerging ophthalmology-focused company with commercial-stage surgical products addressing vision correction.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aurion Biotechnologies

Regenerative Cell Therapyaurionbiotech.com

Aurion Biotech is a clinical-stage regenerative cell therapy company developing allogeneic corneal endothelial cell therapies (neltependocel with rho-kinase inhibitor) for corneal endothelial disease, with Vyznova commercial in Japan and AURN001 in U.S. Phase 3 development.

What Aurion Biotechnologies does

Aurion Biotech is a clinical-stage regenerative cell therapy company developing first-in-class allogeneic therapies for corneal endothelial disease. The company's Corneal Endothelial Cell Therapy (CECT) platform uses natural, unmodified human corneal endothelial cells (neltependocel) delivered with a rho-kinase inhibitor (Y-27632) via intracameral injection. A single donor cornea can yield up to 1,000 therapeutic doses, addressing the documented 1:70 global imbalance between donor corneas and diseased eyes. The portfolio comprises Vyznova (commercial in Japan since 2024 for bullous keratopathy), AURN001 (U.S. Phase 3 with FDA Breakthrough Therapy and RMAT designations), and a cryopreserved formulation in earlier development.

The company generates revenue through commercial sales of Vyznova in Japan following PMDA approval in 2024, with pricing not publicly disclosed and operated on a quote/reimbursement-driven model. U.S. revenue is pre-commercial, pending BLA submission supported by the ASTRA Phase 3 trial initiated at 12 U.S. sites in April 2026. Go-to-market relies on enterprise field sales targeting ophthalmologists and corneal surgeons, with Alcon's majority ownership (2025) providing potential distribution leverage. Aurion's leadership combines deep cell therapy expertise (CEO/CSO Arnaud Lacoste, ex-Novartis cell/gene therapy) with established ophthalmology credentials (CMO Edward Holland, Cincinnati Eye Institute).

Aurion was founded to commercialize foundational research from Professor Shigeru Kinoshita at Kyoto Prefectural University of Medicine, and is now majority-owned by Alcon following the 2025 acquisition. The company is headquartered in Cambridge, MA, with operations in Seattle and Tokyo, and was backed by $120 million in Series A funding led by Deerfield Management in April 2022.

Aurion Biotechnologies firmographics

Firmographics
Name
Aurion Biotechnologies
Legal name
Aurion Biotech, Inc.
Website
https://aurionbiotech.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
101–250 employees
Short description
Aurion Biotech is a clinical-stage regenerative cell therapy company developing allogeneic corneal endothelial cell therapies (neltependocel with rho-kinase inhibitor) for corneal endothelial disease, with Vyznova commercial in Japan and AURN001 in U.S. Phase 3 development.
Ownership category
akta.pro rank

Aurion Biotechnologies industry classification

Industry
Product category
Regenerative Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Corneal cell therapy
  • Regenerative ophthalmology
  • Endothelial disease treatment
  • Allogeneic cell therapy
  • Ophthalmic biologics

Where Aurion Biotechnologies is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Aurion Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Vyznova Commercial Sales (Japan): Aurion Biotech generates revenue from commercial sales of Vyznova in Japan, where it received regulatory and reimbursement approval in 2024. Vyznova is the first cell therapy for corneal endothelial disease commercially available in Japan, indicated for bullous keratopathy.
  2. AURN001 (Future U.S. Commercialization): AURN001 is in Phase 3 development in the U.S. with Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation. Upon FDA approval, the company anticipates commercializing AURN001 as the first cell therapy for corneal endothelial disease in the U.S. market.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Aurion Biotechnologies product offering

Product offering

Core offering

Aurion Biotech develops and manufactures allogeneic cell therapies for corneal endothelial disease, including commercially available Vyznova in Japan and investigational AURN001 in U.S. Phase 3 development. The therapy uses cultured human corneal endothelial cells (neltependocel) combined with a rho-kinase inhibitor (Y-27632), delivered as an intracameral injection to regenerate the corneal endothelium and restore vision. The platform's manufacturing scale enables up to 1,000 therapeutic doses from a single donor cornea.

Product overview

Aurion Biotech is a regenerative cell therapy company developing first-in-class therapies for corneal endothelial disease. The portfolio consists of Vyznova (commercially available in Japan since 2024) as the first-generation product, AURN001 as the lead investigational candidate in U.S. Phase 3 development with BTD/RMAT designation, and a cryopreserved formulation of AURN001 in earlier development to improve distribution accessibility. All products utilize cultured human corneal endothelial cells combined with rho-kinase inhibitor to regenerate corneal clarity.

Differentiator

Problem solved

Functional benefit

Brands

  • Vyznova: First-generation corneal endothelial cell therapy approved by Japan's PMDA for patients with bullous keratopathy. Commercially available in Japan since 2024.
  • AURN001

Products and services

  • Vyznova First-generation corneal endothelial cell therapy approved by Japan's PMDA for patients with bullous keratopathy. Built on a decade of pioneering clinical research in endothelial cell injection, Vyznova is commercially available in Japan since 2024 and is administered to Japanese ophthalmologists and corneal surgeons for the treatment of bullous keratopathy.
  • AURN001 First-in-class combination therapy consisting of natural, unmodified donor endothelial cells (neltependocel) delivered with a rho-kinase inhibitor (Y-27632). Designed to regenerate corneal clarity by repopulating the posterior cornea with functional donor cells. Currently in Phase 3 development in the U.S. with FDA Breakthrough Therapy and RMAT designations granted.
  • Cryopreserved AURN001 Formulation Pipeline program evaluating a cryopreserved formulation of Aurion's endothelial cell therapy in clinical study. Being developed to support broader distribution and treatment accessibility beyond the current fresh-cell formulation.

Quantifiable outcome

  • 65% of high-dose AURN001 patients achieved ≥15-letter BCVA improvement vs 0% in control group (p<0.0001)
  • +5 more outcomes

Companies that use Aurion Biotechnologies

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Aurion Biotechnologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aurion Biotechnologies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Eye Bank Association of America (EBAA)minorStrategic or Co-development PartnerAurion Biotech is an affiliate member of the EBAA. The company presented at EBAA's 2026 Annual Meeting in Indianapolis, participating in a panel on Innovative Solutions. The relationship focuses on education and awareness about regenerative cell therapy as an alternative to traditional transplantation.
  • Kyoto Prefectural University of MedicinecoreStrategic or Co-development PartnerProfessor Shigeru Kinoshita's foundational technology from Kyoto Prefectural University of Medicine underlies Aurion's cell therapy development. His pioneering research in corneal endothelial cell transplantation provided the scientific foundation for the company's therapeutic approach.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Aurion Biotechnologies competitors and assessment

Company assessment

Direct peers

  • jCyte: Clinical-stage cell therapy company developing allogeneic cell therapies for ophthalmic indications. Directly comparable as a peer cell therapy developer in ophthalmology, though focused on retinal indications rather than cornea.
  • Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell therapies for ophthalmology and other indications. Closely comparable as an allogeneic cell therapy developer targeting vision loss with similar manufacturing and regulatory profiles.
  • CorneaGen: Corneal tissue provider and ophthalmology services company serving corneal surgeons with donor tissue and surgical solutions. Direct peer addressing the same corneal surgeon customer base, though operating in the donor tissue supply chain rather than cell therapy.

Broad incumbents

  • Astellas Pharma: Global pharmaceutical company with significant regenerative medicine and cell therapy interests, including historical work on ophthalmology cell therapy via the Astellas Institute for Regenerative Medicine. Comparable as a large incumbent with overlapping cell therapy R&D capabilities.
  • Ocular Therapeutix: Commercial-stage ophthalmology biopharmaceutical company developing therapies for retinal diseases and other eye conditions. Comparable as an ophthalmology-focused biotech with drug delivery and specialty therapeutic capabilities targeting eye care specialists.
  • EyePoint Pharmaceuticals: Specialty ophthalmology company developing sustained-release drug delivery technologies for eye diseases. Comparable as an ophthalmology-focused company addressing unmet needs in vision-threatening conditions with novel delivery approaches.
  • Bausch + Lomb: Global ophthalmology company with a broad portfolio of surgical, pharmaceutical, and consumer eye care products. Comparable as a broad incumbent with established ophthalmology commercial infrastructure and surgical vision care offerings.
  • Glaukos Corporation: Medical technology company focused on novel interventional treatments for glaucoma and corneal disorders. Comparable as an ophthalmology-focused company addressing surgical and disease-modifying therapies in eye care.

Emerging players

  • Krystal Biotech: Commercial-stage biotech pioneering a topical gene therapy platform. Comparable as an emerging biotech applying novel biological platforms to rare diseases with a focus on genetic and regenerative approaches, though in dermatology rather than ophthalmology.
  • RxSight: Commercial-stage ophthalmology company developing adjustable intraocular lens technology for cataract surgery. Comparable as an emerging ophthalmology-focused company with commercial-stage surgical products addressing vision correction.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aurion Biotechnologies social profiles

Digital presence

Aurion Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aurion Biotechnologies leadership team

Management profile

Number of profiles

Profiles11 records

Aurion Biotechnologies subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Aurion Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aurion Biotechnologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurion Biotechnologies

What does Aurion Biotechnologies do?

Aurion Biotech develops and manufactures allogeneic cell therapies for corneal endothelial disease, including commercially available Vyznova in Japan and investigational AURN001 in U.S. Phase 3 development. The therapy uses cultured human corneal endothelial cells (neltependocel) combined with a rho-kinase inhibitor (Y-27632), delivered as an intracameral injection to regenerate the corneal endothelium and restore vision. The platform's manufacturing scale enables up to 1,000 therapeutic doses from a single donor cornea.

Is Aurion Biotechnologies a public or private company?

Aurion Biotechnologies is a private company. It is classified as corporate owned and is currently operating.

When was Aurion Biotechnologies founded?

Aurion Biotechnologies was founded in 2014. It employs 101 to 250 people.

Where is Aurion Biotechnologies based?

Aurion Biotechnologies is headquartered in Seattle, United States, in the North America region.

How does Aurion Biotechnologies make money?

Two revenue lines are on record. Vyznova Commercial Sales (Japan) is the primary driver. The others are AURN001 (Future U.S. Commercialization).

Who are Aurion Biotechnologies's main competitors?

Direct peers on record are jCyte, Lineage Cell Therapeutics and CorneaGen. Broad incumbents are Astellas Pharma, Ocular Therapeutix, EyePoint Pharmaceuticals, Bausch + Lomb and Glaukos Corporation. Emerging players are Krystal Biotech and RxSight.

Does Aurion Biotechnologies have an API?

No public API is recorded for Aurion Biotechnologies.

What industry is Aurion Biotechnologies in?

Aurion Biotechnologies's product category is Regenerative Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageAurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial DysfunctionAurion Biotech completed enrollment in its U.S. ASTRA Phase 3 study of AURN001, a cell therapy for corneal endothelial disease. The study enrolled patients at 12 sites, with the primary endpoint being a ≥15-letter BCVA gain at Month 6. The company plans a U.S. BLA submission following the trial.BioSpaceAurion Biotech Completes Enrollment in Pivotal ASTRA Phase 3 Study, Advancing AURN001 Toward Potential New Treatment for Corneal Edema Secondary to Corneal Endothelial DysfunctionAurion Biotech completed enrollment in its U.S. ASTRA Phase 3 study of AURN001, a cell therapy for corneal edema, across 12 sites. The primary endpoint is a ≥15-letter BCVA gain at Month 6, with a planned U.S. BLA submission. The company aims to advance a global solution for corneal endothelial blindness.YahooIs it a Prudent Move to Retain ALC Stock in Your Portfolio Now?Alcon is expanding its platform through investments and acquisitions, including Aurion Biotech and LumiThera, to support growth. The stock has dipped 8.4% over the past year versus the industry's 2.5% decline, with earnings beating estimates in three of four quarters. New products like Valeda and PanOptix Pro are expected to drive future revenue.BioSpaceAurion Biotech to Highlight Momentum Across Upcoming Eye Bank and Ophthalmology Meetings in JuneAurion Biotech will present at the EBAA 2026 Annual Meeting in Indianapolis and the AECOS 2026 European Symposium in Madrid in June. The company's cell therapy AURN001 is in Phase 3 development, with Vyznova approved in Japan. The presentations highlight unmet needs in corneal endothelial disease.Business Wire BlogAurion Biotech to Give Oral Presentation on Regenerative Cell Therapy for Corneal Endothelial Disease at ASGCT 2026Aurion Biotech will present its lead investigational cell therapy AURN001 at ASGCT 2026 in Boston. The single-administration therapy targets corneal endothelial disease, including Fuchs dystrophy, and is in Phase 3 development. The company also noted Alcon's majority ownership in 2025.Business Wire BlogAurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial DysfunctionAurion Biotech has dosed the first patients in its U.S. ASTRA Phase 3 pivotal study evaluating AURN001, a regenerative cell therapy for corneal edema. This milestone marks a critical step toward the company's U.S. Biologics License Application (BLA) submission and potential approval as the first cell therapy of its kind in the region. The trial involves 12 sites across the United States to assess the efficacy and safety of the treatment compared to a placebo.Investing.comAurion Biotech names Dr. Marjan Farid as advisory board chair By Investing.comAurion Biotech announced the appointment of Dr. Marjan Farid as chair of its medical advisory board; Dr. Farid is a professor and director at the Gavin Herbert Eye Institute at UC-Irvine and chairs the Cornea Clinical Committee of the American Society of Cataract and Refractive Surgery. The company is developing AURN001, an investigational allogeneic cell therapy for corneal endothelial disease, currently in Phase 3 development in the United States, and launched Vyznova commercially in Japan in 2024. Swiss eye care giant Alcon acquired majority ownership of Aurion Biotech in 2025.AETOSWireAurion Biotech Launches Vyznova® (neltependocel) in Japan for the Treatment of Bullous Keratopathy of the CorneaAurion Biotech launched Vyznova (neltependocel) in Japan for bullous keratopathy, the first approved cell therapy for corneal endothelial disease. The company received regulatory and reimbursement approval, and the launch was performed by Professor Shigeru Kinoshita at Kyoto Prefecture University of Medicine.Eyes On EyecareLeadership watch: KALA BIO names new CEO, Aurion Biotech promotes execsAurion Biotech promoted Andrew Torres and Sterling Chung to senior roles ahead of a planned Q1 2026 phase 3 trial for AURON001. KALA BIO named Todd Bazemore CEO, but its phase 2b trial of KPI-012 failed to meet the primary endpoint, prompting evaluation of strategic options and potential workforce cuts.Daily Medical NewsRegenerative approaches to endothelial disease: What’s on the horizon?A medical column reviews emerging regenerative treatments for endothelial disease, highlighting cell injection therapies like Aurion Biotech's AURN001 and Emmecell's EO2002, as well as Trefoil Therapeutics' pharmacological drug TTHX1114. These innovations aim to replace or supplement traditional corneal transplants by offering less invasive procedures, reducing rejection risks, and alleviating donor tissue shortages. Early clinical results indicate significant improvements in visual acuity and faster recovery times compared to standard surgical interventions.